Literature DB >> 1232941

Toxic epidermal necrolysis associated with allopurinol administration.

M H Ellman, D F Fretzin, W Olson.   

Abstract

Allopurinol, now established as a standard form of therapy in hyperuricemia and gout, may be associated with life-threatening skin reactions. This study reports the occurrence of toxic epidermal necrolysis TEN) in three patients receiving Allopurinol. The patients receiving allopurinol. The patients had complicated medical illnesses and were receiving various other medications, but the most apparent common denominator was allopurinol ingestion. Two other cases of TEN and five cases of severe hypersensitivity reactions with vasculitis and extensive skin manifestations, secondary to this drug, have been described in the recent literature. Allopurinol has several unique biochemical and metabolic properties that may increase its ability to cause hypersensitivity or toxic skin reactions.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1232941

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  5 in total

1.  Toxic epidermal necrolysis (Lyell syndrome): more than "acute skin failure".

Authors:  J C Roujeau
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

2.  Desensitisation in a patient with chronic renal disease and severe allergy to allopurinol.

Authors:  A Meyrier
Journal:  Br Med J       Date:  1976-08-21

3.  Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis.

Authors:  J Auböck; P Fritsch
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-29

4.  Toxic epidermal necrolysis in Stevens--Johnson syndrome.

Authors:  D Assaad; L From; D Ricciatti; H Shapero
Journal:  Can Med Assoc J       Date:  1978-01-21       Impact factor: 8.262

Review 5.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.